Breaking News, Collaborations & Alliances

Synaffix Expands ADC Collaboration with MacroGenics

Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales.

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, expanded its license agreement with MacroGenics Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The expansion comes just a year after the original Feb. 2022 deal, increasing the total potentia...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters